Merck & Co. To Present New Data On ZEPATIER (Elbasvir And Grazoprevir) And Chronic Hepatitis C Clinical Development Programs At The Liver Meeting 2016

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting® 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Merck’s HCV clinical development programs. The data include evaluations of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets and the company’s investigational MK-3682B (MK-36821/grazoprevir2/rusazvir) in a broad range of patients with chronic HCV infection. The Liver Meeting® 2016 will take place in Boston, MA, from November 11-15, 2016.